These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27532015)

  • 61. Interphase detection of BCL6/IgH fusion gene in non-Hodgkin lymphoma by fluorescence in situ hybridization.
    Ueda Y; Nishida K; Miki T; Horiike S; Kaneko H; Yokota S; Misawa S; Abe T; Kashima K; Taniwaki M
    Cancer Genet Cytogenet; 1997 Dec; 99(2):102-7. PubMed ID: 9398863
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization.
    Hu Y; Chen W; Chen S; Huang Z
    Onco Targets Ther; 2016; 9():1145-9. PubMed ID: 27042105
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytogenetic Alterations and Correlation with Age and Gender in Patients of Multiple Myeloma: A Study from a Tertiary Care Center in Eastern India.
    Jha K; Saha S; Bhattacharyya M
    South Asian J Cancer; 2024 Apr; 13(2):126-131. PubMed ID: 38919660
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality.
    Gerrie AS; Bruyere H; Chan MJ; Dalal CB; Ramadan KM; Huang SJ; Toze CL; Gillan TL
    Cancer Genet; 2012 Oct; 205(10):523-7. PubMed ID: 22939229
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.
    Reddy KS
    Br J Haematol; 2006 Mar; 132(6):705-22. PubMed ID: 16487171
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification.
    Abdel-Qader HY; Fouad DA; Abuelela SA; Ismail HMA; Boshnaq NH
    Egypt J Med Hum Genet; 2022; 23(1):66. PubMed ID: 37521829
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Detection of chromosome abnormalities using cytoplasmic immunoglobulin staining and FISH in myeloma.
    Mercer BR; Rayeroux KC
    Methods Mol Biol; 2011; 730():159-71. PubMed ID: 21431641
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
    Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma.
    Luo T; Qiang W; Lu J; He H; Liu J; Li L; Jiang H; Fu W; Du J
    Blood Sci; 2021 Jul; 3(3):78-86. PubMed ID: 35402836
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Implementation of cytogenomic microarray with plasma cell enrichment enables better abnormality detection and risk stratification in patients with plasma cell neoplasia than conventional cytogenetics and fluorescence in situ hybridization.
    Chen C; Lim AST; Lau LC; Lim TH; Heng EYH; Tien SL
    Cancer Genet; 2021 Apr; 252-253():25-36. PubMed ID: 33341677
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma.
    Yu Y; Shen H; Liu L; Luo P; Wu S; He J; Tong X; Shang Y; Shao L; Zhou F
    J Vis Exp; 2022 Apr; (182):. PubMed ID: 35499349
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
    Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
    Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.
    Zeng Y; Gao L; Luo X; Chen Y; Kabeer MH; Chen X; Stucky A; Loudon WG; Li SC; Zhang X; Zhong JF
    Mol Oncol; 2018 Jun; 12(7):1004-1011. PubMed ID: 29638042
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
    Martin LD; Harizanova J; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2016 Dec; 55(12):962-974. PubMed ID: 27509849
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH].
    Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Zhang P; Li JY; Chen LJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):686-9. PubMed ID: 22161106
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated with plasma cells as identified by cIg FISH.
    White JS; Zordan A; Batzios C; Campbell LJ
    Cancer Genet; 2012 Dec; 205(12):644-52. PubMed ID: 23200818
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
    Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques.
    Hartmann L; Biggerstaff JS; Chapman DB; Scott JM; Johnson KR; Ghirardelli KM; Fritschle WK; Martinez DL; Bennington RK; de Baca ME; Wells DA; Loken MR; Zehentner BK
    Am J Clin Pathol; 2011 Nov; 136(5):712-20. PubMed ID: 22031309
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
    Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.